Oral Glucose Tolerance Test in Patients with Cystic Fibrosis Compared to the Overweight and Obese: A Different Approach in Understanding the Results

• Published in: Children (Basel) Vol. 9; no. 4; p. 533
• Main Authors: Mogoi, Mirela, Pop, Liviu Laurentiu, Dediu, Mihaela, Ciuca, Ioana Mihaiela
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.04.2022; MDPI
• Subjects: abnormal glucose tolerance; Age; alternative methods; Body mass index; Cystic fibrosis; Diabetes; Glucose; Laboratories; Metabolism; Mutation; Obesity; oral glucose tolerance test; Overweight; Pediatrics; Statistical analysis; alternative methods; oral glucose tolerance test; abnormal glucose tolerance; cystic fibrosis; obesity
• ISSN: 2227-9067; 2227-9067
• DOI: 10.3390/children9040533

(1) Background: In cystic fibrosis (CF), the oral glucose tolerance test (OGTT) is recommended from 10 years old annually to screen and diagnose cystic fibrosis-related diabetes (CFRD). Alternative OGTT characteristics (glucose curve shape, time to glucose peak, one-hour glucose value, and three-hour glucose value with the new shape curve) were studied in other populations considered at high risk for diabetes; (2) Methods: The study analyses classical and alternative OGGT characteristics from 44 children (22 CF, 22 obese without CF), mean age: 12.9 ± 2.2 years evaluated in a single-center from Romania. (3) Results: In 59.1% of children with CF, the predominant OGTT pattern was: abnormal glucose metabolism or CFRD, with a monophasic curve shape, a late peak glucose level, and 1 h glucose ≥ 155 mg/dL, showing a very different pattern compared with sex and age-matched obese children. Statistical estimation agreement between the late glucose peak (K = 0.60; = 0.005), the 1 h glucose ≥ 155 mg/dL during OGTT (K = 0.69, = 0.001), and the classical method of interpretation was found. (4) Conclusions: Late peak glucose and 1 h glucose level ≥ 155 mg/dL during OGTT can be used for diagnosing the early glucose metabolism alteration in children with CF.